QTTB · Q32 Bio Inc.
$14.65
-1.07 (-6.78%)
At close · Jul 29
Market Cap
$266.39M
Shares
16.96M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.71
Open$15.71
Day$14.79–15.88
52W$1.57–23.57
Avg vol 30d1.9M
Short int2.3M · 13.3% float · 1.0d
Short vol44%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+152%
above
Price vs 50-day avg
+28%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
64%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+295%
trailing
YTD return
+373%
this year
Relative strength
+287%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $6 — 50d above 200d
Institutional flow
Distributing
5 of 53 funds reported for Jun 30 · net -21.4K sh shares
Insider flow
Accumulating
Net +$30.0M over 90 days · 0% sells
Short interest
Rising
13.35% of float · ▲ +234.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 2-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+137%
Y/Y
Free cash flow
$-33.5M
Valuation
P/E 5.7
in line
Balance sheet
$48.3M
net cash
Quant / Vol
risk profile
Volatility
175%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+152%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
64%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $6 — 50d above 200d
Institutional flow
Distributing
5 of 53 funds reported for Jun 30 · net -21.4K sh shares
Insider flow
Accumulating
Net +$30.0M over 90 days · 0% sells
Short interest
Rising
13.35% of float · ▲ +234.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $2
Now $16 · 64%
52-wk high $24
vs 200-day avg +152%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QTTB
this stock
Q32 Bio Inc.
|
$266.39M | +373.2% | +100.0% | 5.7 | 13.3% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QTTB | +4.5% | +19.3% | +294.7% | +23.3% | +373.2% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +5.4% | +19.3% | +287.3% | +24.1% | +364.6% |